Interpretation and applicability of microRNA data to the context of








































The microRNA (miRNA)-guided RNA silencing 
pathway is a gene regulatory process present in almost 
all eukaryotic cells and based on small non-coding 
RNAs known as miRNAs [1]. Generated by the 
ribonuclease III Dicer, miRNAs are key regulators of 
gene expression that act mainly through recognition of 
specific binding sites generally located in the 3’ 
untranslated region of specific messenger RNAs 
(mRNAs). Predicted to regulate up to 90% of the genes 
in humans [2], miRNAs may control every cellular 
processes in all cells and tissues of the human body! 
Required for the fine tuning and tight regulation of 
cellular protein expression, a normal miRNA function is 








































disease [3]. Deregulation of protein expression induced 
by a dysfunctional miRNA-based regulatory system, 
which may be either global or miRNA-specific in 
nature, may thus represent the main etiologic factor 
underlying age-related diseases, such as Alzheimer’s 
disease (AD) that affects the brain (Provost, manuscript 
submitted).  
 
MicroRNAs and Alzheimer’s disease 
 
AD is a slowly progressing, age-related neurodegenera-
tive disease that currently affects ~2% of the population 
in industrialized countries and whose incidence is 
predicted to increase dramatically over the next 40 years 
(http://www.alz.org) [4]. Affecting cholinergic neurons, 
AD is characterized by the accumulation of plaques 
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hippocampal region of the brain [5]. Aß peptides are 
produced upon proteolytic cleavage of APP by ß-
secretase, also known as ß-site APP-cleaving enzyme 1 
(BACE1), which contributes to the formation of these 
plaques [6] (Provost, manuscript submitted).  
 
Post-mortem analyses have revealed upregulation of 
BACE1 expression at the protein, but not at the mRNA, 
level in brains from patients suffering from AD, as 
compared to brains from unaffected patients [7], 
consistent with an impaired control of BACE1 mRNA 
translation. In a recent study from our laboratory, we 
reported similar observations in an animal model of AD 
(APPSwe/PS1 mice) and demonstrated a role for two 
miRNAs, i.e. miR-298 and miR-328, in the regulation 
of BACE1 expression, using mainly transiently 
transfected murine neuronal N2a cells in culture [8]. In 
vivo, we observed decreased expression levels of miR-
298 and miR-328 in the hippocampus of aging 
APPSwe/PS1 mice [8], which supports further the 
possibility that the loss of miRNA regulation of BACE1 
mRNA translation may lead to higher BACE1 protein 
expression, an enhanced Aß formation and the 




Whether these findings can be extrapolated and 
transposed to human requires prudence and cautious-
ness, especially in the context of multifactorial, age-
related diseases like AD, which may result from an 
intricate interplay of genetic and environmental factors. 
Several additional issues warrant further considerations 
and need to be taken into account, or addressed, in order 
to ascertain our interpretation of miRNA data and, most 
importantly, the transposability of our findings to the 
aging human beings, such as (i) the nature and source of 
the biological material under investigation, (ii) the use 
and relevance of cellular models, (iii) the use of primary 
versus cultured cells, and (iv) the other functions 
exerted by miRNAs.  
 
Nature and source of the biological material under 
investigation 
 
The most obvious limitation here pertains to the use of 
mice and the (non-)conservation of miRNA and BACE1 
mRNA sequences and function between species, as 
discussed previously [8]. In addition, although very 
useful for the study of specific aspects of the disease, 
the animal models of AD that are currently available, in 
which the disease is caused by altering genes involved 
in Aß metabolism (eg, mutation of the presenilin 1 gene 
combined with a chimeric mouse/human APP), only 
imperfectly mimic and oversimplify a multifactorial 
disease as complex as AD. In addition, whether the 
observed changes in miRNA levels in the aging AD 
brain are the cause or a consequence of the disease (the 
chicken or the egg dilemma) remains disputable. 
 
Moreover, since the disease is induced “artificially”, 
and does not occur or progress “naturally” in these 
animals, only the contributory, and not the possible 
causal, role of miRNAs in the etiology and/or 
progression of AD can be investigated. For that 
purpose, the targeted deletion or functional alteration of 
miRNA function, followed by monitoring of cognitive 
functions, would be more appropriate.  
 
Animal models may also be more suitable and provide 
more insights into the pathogenesis of AD progression 
as compared to humans, where brain tissues may only 
be obtained, and the data collected, at the time of death, 
although harvesting brains from subjects of different 
ages may partially circumvent this issue. In contrast to 
studies performed in mice, results obtained from post-
mortem human brain tissues may be markedly 
influenced by the time interval between the patients’ 
death and brain tissue harvesting, due to the relatively 
short half-lives of some miRNAs (~1 to 3.5 h), as 
recently reported by Sethi and Lukiw [9].  
 
Use and relevance of cellular models 
 
It is important to underline the utility of cellular models 
in complementing molecular, biochemical or animal 
studies. As such, cultured neuronal N2a cells, which 
have been used to obtain most of the experimental 
evidences pertaining to the miRNA repression of 
BACE1 expression [8], are highly relevant and 
represent the most practical cellular system to study the 
molecular mechanisms underlying AD.  
 
Whereas specific cell lines, such as 293 or 293T cells, 
are immortalized upon transformation with adeno-
viruses and/or simian virus 40 infection, the cell clone 
Neuro-2a (N2a) was established from a spontaneous 
neuroblastoma isolated from the brain of a strain A 
albino mouse (please refer to http://www.atcc.org). 
Cytogenetic analysis of these cells revealed an unstable 
karyotype within a stemline range of 94 to 98 chromo-
somes (the cells contain 6 to 10 large chromosomes 
with median or submedian centromeres and 2 to 4 
minute chromosomes). Although N2a cells are of 
neuronal origin, the endogenous biochemical processes 
in such cells, that may have undergone tens to hundreds 
of passages at the time of harvesting, are expected to 
differ quite markedly from that of primary neuronal 
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can be reached from their use. 
 
Use of primary versus cultured cells 
 
The main issue here pertains to two fundamental 
differences distinguishing primary cells or tissues from 
immortalized, cultured cells: the genome integrity of the 
latter and their propensity for cell division. The 
implication of these differences in the interpretation of 
miRNA data, which was highlighted not too long ago 
[10], is major: Previously known as repressors of 
mRNA translation, miRNAs have also been shown to 
enhance mRNA translation upon cell cycle arrest [10]. 
Whether miRNAs function similarly in cell cycle-
arrested and primary, non-dividing cells remains to be 
established. However, the experimental evidences are 
sufficiently strong to raise a imperative issue as to 
whether primary, non-dividing cells, such as cholinergic 
neurons, support miRNA repression and/or 
enhancement of mRNA translation. This observation 
also imply that all the miRNA data obtained from 
cultured cells should be intrepreted with great caution 
before transposing them to in vivo situations, as 
miRNAs found to repress specific mRNAs in 
immortalized cultured cells may exert the exact 
opposite effects in primary cells or tissues in vivo. 
Hence to need to obtain data or additional evidences 
from primary cells that either support or challenge our 
in vitro miRNA data.  
 
Other functions exerted by microRNAs 
 
A recent study by Eiring et al. [11] revealed another 
mean by which miRNAs may enhance gene expression. 
Reported to regulate BACE1 mRNA translation in the 
context of AD [8], miR-328 has been shown to have a 
second function, acting as an RNA decoy by binding to 
heterogeneous nuclear ribonucleoprotein E2 and lifting 
its translational repression of an mRNA involved in 
myeloid cell differentiation [11, 12]. Therefore, any 
decrease or increase in miRNA levels may not yield the 
expected relief or accentuated repression of gene 
expression, respectively. This phenomenon may also 
explain, at least in some cases, the lack of any 
phenotypic changes associated to specific or global 
miRNA variations, both in terms of levels and mode of 
action, the cumulative effects of which may cancel each 
other out.  
 
Another level of complexity may be conferred by the 
ability of miRNAs to regulate multiple mRNA targets, 
to exert indirect effects and to be involved in more 
complex networks of regulatory mediators of 
importance in the pathogenesis of age-related diseases 
like AD.  
 
CONCLUSION AND PERSPECTIVES 
 
Recently, the major research advances pertaining to the 
possible role and function of miRNAs in 
neurodegenerative diseases, such as AD, has provided 
novel perspectives to the pathogenesis of increasingly 
prevalent, age-related diseases in human. However, 
further investigations are required in order to improve 
our understanding of the changes that may occur in 
miRNA biogenesis, metabolism and/or function during 
aging, which may be an important contributor to the 
etiology and progression of age-related diseases. In this 
regard, several issues related to the impact of aging 
and/or cell division on the integrity and functionality of 
the miRNA pathway remain to be explored and might 
add an additional layer of complexity to miRNA studies 
involving mRNA translational regulation: Is the 
biogenesis and/or function of miRNAs modified as the 
cells are dividing, or altered by age-related processes? 
Are miRNA genes shut off or turned on, either 
specifically or globally, during aging? Do cells acquire 
or lose functional miRNAs as they age? As they divide?  
 
In that context, prudence and cautiousness should guide 
us when interpreting and extrapolating experimental 
findings related to miRNAs to a human disease in 
particular. In AD, for instance, primary human brain 
tissues obtained upon death of AD and non-AD patients 
remain the most relevant source of biological materials 
in order to get further insights into the pathogenesis of 
AD. However, the utility, versatility and comple-
mentarity of animal and cell culture models, albeit 
imperfect and coming with their pros and cons, cannot 
be ignored, as the insights they provide simply need to 
be considered into their proper context with their own 
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